Testing effectiveness (Phase 2)WithdrawnNCT01288092
What this trial is testing
BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer
Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals